{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:41:36Z","timestamp":1758267696821,"version":"3.40.3"},"publisher-location":"Cham","reference-count":148,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319492827"},{"type":"electronic","value":"9783319492841"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/82_2016_495","type":"book-chapter","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T14:58:24Z","timestamp":1467385104000},"page":"207-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy"],"prefix":"10.1007","author":[{"given":"Kai","family":"Schulze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ebensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Riese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair","family":"Prochnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus-Michael","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,2]]},"reference":[{"issue":"9","key":"495_CR1","doi-asserted-by":"publisher","first-page":"e3116","DOI":"10.1371\/journal.pone.0003116","volume":"3","author":"EM Agger","year":"2008","unstructured":"Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C et al (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3(9):e3116","journal-title":"PLoS One"},{"issue":"1","key":"495_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1208\/s12248-013-9550-y","volume":"16","author":"IA Aljuffali","year":"2014","unstructured":"Aljuffali IA, Sung CT, Shen FM, Huang CT, Fang JY (2014) Squarticles as a lipid nanocarrier for delivering diphencyprone and minoxidil to hair follicles and human dermal papilla cells. AAPS J 16(1):140\u2013150","journal-title":"AAPS J"},{"issue":"2\u20133","key":"495_CR3","first-page":"141","volume":"45","author":"AC Allison","year":"1997","unstructured":"Allison AC (1997) Immunological adjuvants and their modes of action. Arch Immunol Ther Exp (Warsz) 45(2\u20133):141\u2013147","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"10","key":"495_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20070784","volume":"204","author":"JR Almeida","year":"2007","unstructured":"Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E et al (2007) Superior control of HIV-1 replication by CD8+\u00a0T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204(10):2473\u20132485","journal-title":"J Exp Med"},{"issue":"43","key":"495_CR5","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1016\/j.vaccine.2014.07.097","volume":"32","author":"CS Ambrose","year":"2014","unstructured":"Ambrose CS, Wu X, Caspard H, Belshe RB (2014) Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity. Vaccine 32(43):5546\u20135548","journal-title":"Vaccine"},{"issue":"Suppl 5","key":"495_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1469-0691.2012.03995.x","volume":"18","author":"F Anjuere","year":"2012","unstructured":"Anjuere F, Bekri S, Bihl F, Braud VM, Cuburu N, Czerkinsky C et al (2012) B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells. Clin Microbiol Infect 18(Suppl 5):117\u2013122","journal-title":"Clin Microbiol Infect"},{"issue":"25","key":"495_CR7","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2010.04.026","volume":"28","author":"BJ Baaten","year":"2010","unstructured":"Baaten BJ, Clarke B, Strong P, Hou S (2010) Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue. Vaccine 28(25):4130\u20134137","journal-title":"Vaccine"},{"issue":"35","key":"495_CR8","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1016\/j.vaccine.2015.03.080","volume":"33","author":"O Badillo-Godinez","year":"2015","unstructured":"Badillo-Godinez O, Gutierrez-Xicotencatl L, Plett-Torres T, Pedroza-Saavedra A, Gonzalez-Jaimes A, Chihu-Amparan L et al (2015) Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice. Vaccine 33(35):4228\u20134237","journal-title":"Vaccine"},{"issue":"3","key":"495_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jconrel.2010.09.018","volume":"148","author":"SM Bal","year":"2010","unstructured":"Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA (2010) Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 148(3):266\u2013282","journal-title":"J Control Release"},{"issue":"4","key":"495_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clindermatol.2011.01.006","volume":"29","author":"C Bangert","year":"2011","unstructured":"Bangert C, Brunner PM, Stingl G (2011) Immune functions of the skin. Clin Dermatol 29(4):360\u2013376","journal-title":"Clin Dermatol"},{"issue":"25","key":"495_CR11","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1016\/j.vaccine.2005.11.008","volume":"24","author":"PD Becker","year":"2006","unstructured":"Becker PD, Fiorentini S, Link C, Tosti G, Ebensen T, Caruso A et al (2006) The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2\/6 agonist MALP-2 as mucosal adjuvant. Vaccine 24(25):5269\u20135276","journal-title":"Vaccine"},{"issue":"5","key":"495_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/ni.1724","volume":"10","author":"S Bedoui","year":"2009","unstructured":"Bedoui S, Whitney PG, Waithman J, Eidsmo L, Wakim L, Caminschi I et al (2009) Cross-presentation of viral and self antigens by skin-derived CD103+\u00a0dendritic cells. Nat Immunol 10(5):488\u2013495","journal-title":"Nat Immunol"},{"issue":"3","key":"495_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S1473-3099(13)70297-4","volume":"14","author":"RH Behrens","year":"2014","unstructured":"Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D et al (2014) Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 14(3):197\u2013204","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"495_CR14","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1128\/IAI.70.6.3012-3019.2002","volume":"70","author":"AS Beignon","year":"2002","unstructured":"Beignon AS, Briand JP, Rappuoli R, Muller S, Partidos CD (2002) The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. Infect Immun 70(6):3012\u20133019","journal-title":"Infect Immun"},{"issue":"4","key":"495_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ymeth.2009.04.015","volume":"49","author":"E Bennett","year":"2009","unstructured":"Bennett E, Mullen AB, Ferro VA (2009) Translational modifications to improve vaccine efficacy in an oral influenza vaccine. Methods 49(4):322\u2013327","journal-title":"Methods"},{"issue":"1","key":"495_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4049\/jimmunol.1301812","volume":"192","author":"SM Blaauboer","year":"2014","unstructured":"Blaauboer SM, Gabrielle VD, Jin L (2014) MPYS\/STING-mediated TNF-alpha, not type I IFN, is essential for the mucosal adjuvant activity of (3\u2019-5\u2019)-cyclic-di-guanosine-monophosphate in vivo. J Immunol 192(1):492\u2013502","journal-title":"J Immunol"},{"issue":"2","key":"495_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4161\/hv.26796","volume":"10","author":"A Bolhassani","year":"2014","unstructured":"Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM (2014) Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. Hum Vaccines Immunotherapeutics 10(2):321\u2013332","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"6","key":"495_CR18","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1002\/eji.200323954","volume":"33","author":"S Borsutzky","year":"2003","unstructured":"Borsutzky S, Fiorelli V, Ebensen T, Tripiciano A, Rharbaoui F, Scoglio A et al (2003) Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol 33(6):1548\u20131556","journal-title":"Eur J Immunol"},{"issue":"2\u20133","key":"495_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0264-410X(00)00171-7","volume":"19","author":"TG Boyce","year":"2000","unstructured":"Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, Zhu Y et al (2000) Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19(2\u20133):217\u2013226","journal-title":"Vaccine"},{"issue":"3","key":"495_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/sj.gt.3301886","volume":"10","author":"J Bramson","year":"2003","unstructured":"Bramson J, Dayball K, Evelegh C, Wan YH, Page D, Smith A (2003) Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther 10(3):251\u2013260","journal-title":"Gene Ther"},{"issue":"30","key":"495_CR21","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1016\/j.vaccine.2006.12.001","volume":"25","author":"P Brandtzaeg","year":"2007","unstructured":"Brandtzaeg P (2007) Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25(30):5467\u20135484","journal-title":"Vaccine"},{"issue":"7370","key":"495_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature10429","volume":"478","author":"DL Burdette","year":"2011","unstructured":"Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M et al (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478(7370):515\u2013518","journal-title":"Nature"},{"issue":"9","key":"495_CR23","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1166\/jbn.2014.1984","volume":"10","author":"LA Caetano","year":"2014","unstructured":"Caetano LA, Almeida AJ, Goncalves LM (2014) Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review. J Biomed Nanotechnol 10(9):2295\u20132316","journal-title":"J Biomed Nanotechnol"},{"issue":"8","key":"495_CR24","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1182\/blood-2008-05-155176","volume":"112","author":"I Caminschi","year":"2008","unstructured":"Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, Lo JC et al (2008) The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112(8):3264\u20133273","journal-title":"Blood"},{"issue":"12","key":"495_CR25","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","volume":"71","author":"NJ Carter","year":"2011","unstructured":"Carter NJ, Curran MP (2011) Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71(12):1591\u20131622","journal-title":"Drugs"},{"issue":"4","key":"495_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/14712590902849224","volume":"9","author":"S Chadwick","year":"2009","unstructured":"Chadwick S, Kriegel C, Amiji M (2009) Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 9(4):427\u2013440","journal-title":"Expert Opin Biol Ther"},{"issue":"1\u20132","key":"495_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.virusres.2004.02.027","volume":"103","author":"D Chen","year":"2004","unstructured":"Chen D, Burger M, Chu Q, Endres R, Zuleger C, Dean H et al (2004) Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity. Virus Res 103(1\u20132):147\u2013153","journal-title":"Virus Res"},{"key":"495_CR28","unstructured":"ClinicalTrials.gov (2012) A service of the U.S. National Institutes of Health. Trial on the safety of a new liposomal adjuvant system, CAF01, when given with the tuberculosis subunit vaccine Ag85B-ESAT-6 as two injections with two months interval to healthy adult volunteers. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00922363"},{"issue":"5","key":"495_CR29","doi-asserted-by":"publisher","first-page":"e10818","DOI":"10.1371\/journal.pone.0010818","volume":"5","author":"B Combadiere","year":"2010","unstructured":"Combadiere B, Vogt A, Mahe B, Costagliola D, Hadam S, Bonduelle O et al (2010) Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 5(5):e10818","journal-title":"PLoS One"},{"issue":"3","key":"495_CR30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1051\/vetres:2006014","volume":"37","author":"E Cox","year":"2006","unstructured":"Cox E, Verdonck F, Vanrompay D, Goddeeris B (2006) Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 37(3):511\u2013539","journal-title":"Vet Res"},{"issue":"7","key":"495_CR31","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20092532","volume":"207","author":"PA Darrah","year":"2010","unstructured":"Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M et al (2010) IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207(7):1421\u20131433","journal-title":"J Exp Med"},{"issue":"7","key":"495_CR32","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ et al (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13(7):843\u2013850","journal-title":"Nat Med"},{"key":"495_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.addr.2015.03.007","volume":"91","author":"CJ Davitt","year":"2015","unstructured":"Davitt CJ, Lavelle EC (2015) Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliv Rev 91:52\u201369","journal-title":"Adv Drug Deliv Rev"},{"issue":"16","key":"495_CR34","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1002\/anie.201200048","volume":"51","author":"BG De Geest","year":"2012","unstructured":"De Geest BG, Willart MA, Lambrecht BN, Pollard C, Vervaet C, Remon JP et al (2012) Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. Angew Chem Int Edit 51(16):3862\u20133866","journal-title":"Angew Chem Int Edit"},{"issue":"2","key":"495_CR35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0003-2697(81)90006-3","volume":"115","author":"E De Vendittis","year":"1981","unstructured":"De Vendittis E, Palumbo G, Parlato G, Bocchini V (1981) A fluorimetric method for the estimation of the critical micelle concentration of surfactants. Anal Biochem 115(2):278\u2013286","journal-title":"Anal Biochem"},{"issue":"8","key":"495_CR36","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.nano.2014.06.003","volume":"10","author":"T Demoulins","year":"2014","unstructured":"Demoulins T, Milona P, McCullough KC (2014) Alginate-coated chitosan nanogels differentially modulate class-A and class-B CpG-ODN targeting of dendritic cells and intracellular delivery. Nanomed Nanotechnol Biol Med 10(8):1739\u20131749","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"495_CR37","doi-asserted-by":"crossref","unstructured":"des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116(1):1\u201327","DOI":"10.1016\/j.jconrel.2006.08.013"},{"issue":"Suppl 1","key":"495_CR38","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1016\/j.vaccine.2011.04.119","volume":"29","author":"R Dhere","year":"2011","unstructured":"Dhere R, Yeolekar L, Kulkarni P, Menon R, Vaidya V, Ganguly M et al (2011) A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 29(Suppl 1):A16\u2013A21","journal-title":"Vaccine"},{"issue":"1","key":"495_CR39","first-page":"1","volume":"58","author":"H Dlugonska","year":"2012","unstructured":"Dlugonska H, Grzybowski M (2012) Mucosal vaccination\u2013an old but still vital strategy. Ann Parasitol 58(1):1\u20138","journal-title":"Ann Parasitol"},{"issue":"32","key":"495_CR40","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1016\/j.vaccine.2011.05.026","volume":"29","author":"T Ebensen","year":"2011","unstructured":"Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzman CA (2011) Bis-(3\u2019,5\u2019)-cyclic dimeric adenosine monophosphate: strong Th1\/Th2\/Th17 promoting mucosal adjuvant. Vaccine 29(32):5210\u20135220","journal-title":"Vaccine"},{"issue":"4","key":"495_CR41","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.4049\/jimmunol.179.4.2065","volume":"179","author":"T Ebensen","year":"2007","unstructured":"Ebensen T, Link C, Riese P, Schulze K, Morr M, Guzman CA (2007a) A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties. J Immunol 179(4):2065\u20132073","journal-title":"J Immunol"},{"issue":"8","key":"495_CR42","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1128\/CVI.00119-07","volume":"14","author":"T Ebensen","year":"2007","unstructured":"Ebensen T, Schulze K, Riese P, Morr M, Guzman CA (2007b) The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol CVI 14(8):952\u2013958","journal-title":"Clin Vaccine Immunol CVI"},{"issue":"16","key":"495_CR43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa0800390","volume":"359","author":"Nasr El-Sayed","year":"2008","unstructured":"el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A et al (2008) Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 359(16):1655\u20131665","journal-title":"New England Journal of Medicine"},{"issue":"37","key":"495_CR44","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1016\/j.vaccine.2015.05.012","volume":"33","author":"L Engelke","year":"2015","unstructured":"Engelke L, Winter G, Hook S, Engert J (2015) Recent insights into cutaneous immunization: how to vaccinate via the skin. Vaccine 33(37):4663\u20134674","journal-title":"Vaccine"},{"issue":"39\u201340","key":"495_CR45","doi-asserted-by":"publisher","first-page":"6891","DOI":"10.1016\/j.vaccine.2007.07.014","volume":"25","author":"N Etchart","year":"2007","unstructured":"Etchart N, Hennino A, Friede M, Dahel K, Dupouy M, Goujon-Henry C et al (2007) Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 25(39\u201340):6891\u20136899","journal-title":"Vaccine"},{"issue":"15","key":"495_CR46","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1016\/j.vaccine.2005.12.048","volume":"24","author":"MA Franco","year":"2006","unstructured":"Franco MA, Angel J, Greenberg HB (2006) Immunity and correlates of protection for rotavirus vaccines. Vaccine 24(15):2718\u20132731","journal-title":"Vaccine"},{"issue":"9629","key":"495_CR47","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(08)60839-9","volume":"371","author":"SA Frech","year":"2008","unstructured":"Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF et al (2008) Use of a patch containing heat-labile toxin from Escherichia coli against travellers\u2019 diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371(9629):2019\u20132025","journal-title":"Lancet"},{"issue":"34","key":"495_CR48","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1016\/j.vaccine.2011.06.010","volume":"29","author":"RW Frenck Jr","year":"2011","unstructured":"Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J et al (2011) Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 29(34):5666\u20135674","journal-title":"Vaccine"},{"issue":"5","key":"495_CR49","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1586\/14760584.6.5.809","volume":"6","author":"GM Glenn","year":"2007","unstructured":"Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC et al (2007) Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 6(5):809\u2013819","journal-title":"Expert Rev Vaccines"},{"issue":"17","key":"495_CR50","doi-asserted-by":"publisher","first-page":"10134","DOI":"10.1128\/JVI.00647-14","volume":"88","author":"F Graw","year":"2014","unstructured":"Graw F, Regoes RR (2014) Predicting the impact of CD8+\u00a0T cell polyfunctionality on HIV disease progression. J Virol 88(17):10134\u201310145","journal-title":"J Virol"},{"issue":"14","key":"495_CR51","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.vaccine.2013.08.020","volume":"32","author":"LM Hafner","year":"2014","unstructured":"Hafner LM, Wilson DP, Timms P (2014) Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 32(14):1563\u20131571","journal-title":"Vaccine"},{"issue":"10","key":"495_CR52","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.4049\/jimmunol.178.10.6259","volume":"178","author":"LZ He","year":"2007","unstructured":"He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA et al (2007) Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 178(10):6259\u20136267","journal-title":"J Immunol"},{"issue":"23","key":"495_CR53","doi-asserted-by":"publisher","first-page":"11756","DOI":"10.1128\/JVI.01460-06","volume":"80","author":"XS He","year":"2006","unstructured":"He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB et al (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80(23):11756\u201311766","journal-title":"J Virol"},{"issue":"10","key":"495_CR54","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/ni.2680","volume":"14","author":"WR Heath","year":"2013","unstructured":"Heath WR, Carbone FR (2013) The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol 14(10):978\u2013985","journal-title":"Nat Immunol"},{"issue":"10","key":"495_CR55","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.vaccine.2011.12.130","volume":"30","author":"S Hirobe","year":"2012","unstructured":"Hirobe S, Matsuo K, Quan YS, Kamiyama F, Morito H, Asada H et al (2012) Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine 30(10):1847\u20131854","journal-title":"Vaccine"},{"issue":"5","key":"495_CR56","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/j.1365-2958.2005.04632.x","volume":"56","author":"KB Hisert","year":"2005","unstructured":"Hisert KB, MacCoss M, Shiloh MU, Darwin KH, Singh S, Jones RA et al (2005) A glutamate-alanine-leucine (EAL) domain protein of Salmonella controls bacterial survival in mice, antioxidant defence and killing of macrophages: role of cyclic diGMP. Mol Microbiol 56(5):1234\u20131245","journal-title":"Mol Microbiol"},{"issue":"2","key":"495_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.imlet.2004.11.009","volume":"97","author":"J Holmgren","year":"2005","unstructured":"Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, Eriksson K et al (2005) Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97(2):181\u2013188","journal-title":"Immunol Lett"},{"issue":"4 Suppl","key":"495_CR58","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/nm1213","volume":"11","author":"J Holmgren","year":"2005","unstructured":"Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11(4 Suppl):S45\u2013S53","journal-title":"Nat Med"},{"issue":"12","key":"495_CR59","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.humpath.2004.09.008","volume":"35","author":"K Honma","year":"2004","unstructured":"Honma K, Abraham JL, Chiyotani K, De Vuyst P, Dumortier P, Gibbs AR et al (2004) Proposed criteria for mixed-dust pneumoconiosis: definition, descriptions, and guidelines for pathologic diagnosis and clinical correlation. Hum Pathol 35(12):1515\u20131523","journal-title":"Hum Pathol"},{"issue":"1","key":"495_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4161\/hv.8.1.18419","volume":"8","author":"G Icardi","year":"2012","unstructured":"Icardi G, Orsi A, Ceravolo A, Ansaldi F (2012) Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum Vaccines immunotherapeutics 8(1):67\u201375","journal-title":"Hum Vaccines immunotherapeutics"},{"key":"495_CR61","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.taap.2016.01.005","volume":"299","author":"Anna N. Ilinskaya","year":"2016","unstructured":"Ilinskaya AN, Dobrovolskaia MA (2016) Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol 299:70\u201377","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"13","key":"495_CR62","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/0961203309345724","volume":"18","author":"E Israeli","year":"2009","unstructured":"Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Adjuvants and autoimmunity. Lupus 18(13):1217\u20131225","journal-title":"Lupus"},{"issue":"6","key":"495_CR63","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1517\/17425247.2015.1044435","volume":"12","author":"Y Jia","year":"2015","unstructured":"Jia Y, Krishnan L, Omri A (2015) Nasal and pulmonary vaccine delivery using particulate carriers. Expert Opin Drug Deliv 12(6):993\u20131008","journal-title":"Expert Opin Drug Deliv"},{"issue":"16","key":"495_CR64","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1128\/JVI.00228-07","volume":"81","author":"S Kannanganat","year":"2007","unstructured":"Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR (2007) Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81(16):8468\u20138476","journal-title":"J Virol"},{"key":"495_CR65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-chembioeng-073009-100948","volume":"1","author":"P Karande","year":"2010","unstructured":"Karande P, Mitragotri S (2010) Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu Rev Chem Biomol 1:175\u2013201","journal-title":"Annu Rev Chem Biomol"},{"issue":"4","key":"495_CR66","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.nano.2015.12.372","volume":"12","author":"Monika Kaurav","year":"2016","unstructured":"Kaurav M, Minz S, Sahu K, Kumar M, Madan J, Pandey RS (2016) Nanoparticulate mediated transcutaneous immunization: Myth or reality. Nanomed Nanotechnol Biol Med 12:1063\u20131081","journal-title":"Nanomedicine: Nanotechnology, Biology and Medicine"},{"key":"495_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-3-642-00477-3_7","volume":"197","author":"MA Kendall","year":"2010","unstructured":"Kendall MA (2010) Needle-free vaccine injection. Handb Exp Pharmacol 197:193\u2013219","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"495_CR68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/649228","volume":"201","author":"YC Kim","year":"2010","unstructured":"Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR (2010) Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 201(2):190\u2013198","journal-title":"J Infect Dis"},{"key":"495_CR69","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jconrel.2014.05.060","volume":"190","author":"H Kraan","year":"2014","unstructured":"Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP (2014) Buccal and sublingual vaccine delivery. J Control Release 190:580\u2013592","journal-title":"J Control Release"},{"issue":"8","key":"495_CR70","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1128\/AAC.49.8.3435-3441.2005","volume":"49","author":"E Kugelberg","year":"2005","unstructured":"Kugelberg E, Norstrom T, Petersen TK, Duvold T, Andersson DI, Hughes D (2005) Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 49(8):3435\u20133441","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"495_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1586\/14760584.6.2.133","volume":"6","author":"M Kundi","year":"2007","unstructured":"Kundi M (2007) New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6(2):133\u2013140","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"495_CR72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.biopha.2004.04.009","volume":"58","author":"Y Kuroda","year":"2004","unstructured":"Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M (2004) Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 58(5):325\u2013337","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"495_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2010.12.014","volume":"54","author":"MN Kweon","year":"2011","unstructured":"Kweon MN (2011) Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 54(1):1\u20135","journal-title":"Cytokine"},{"issue":"49","key":"495_CR74","doi-asserted-by":"publisher","first-page":"6711","DOI":"10.1016\/j.vaccine.2014.08.089","volume":"32","author":"A Lamichhane","year":"2014","unstructured":"Lamichhane A, Azegamia T, Kiyonoa H (2014) The mucosal immune system for vaccine development. Vaccine 32(49):6711\u20136723","journal-title":"Vaccine"},{"issue":"1","key":"495_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4161\/hv.34299","volume":"11","author":"C Levin","year":"2015","unstructured":"Levin C, Perrin H, Combadiere B (2015) Tailored immunity by skin antigen-presenting cells. Hum Vaccines immunotherapeutics 11(1):27\u201336","journal-title":"Hum Vaccines immunotherapeutics"},{"issue":"37","key":"495_CR76","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1016\/j.vaccine.2011.04.080","volume":"29","author":"C Liard","year":"2011","unstructured":"Liard C, Munier S, Arias M, Joulin-Giet A, Bonduelle O, Duffy D et al (2011) Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 29(37):6379\u20136391","journal-title":"Vaccine"},{"issue":"3","key":"495_CR77","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/eji.200324511","volume":"34","author":"C Link","year":"2004","unstructured":"Link C, Gavioli R, Ebensen T, Canella A, Reinhard E, Guzman CA (2004) The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol 34(3):899\u2013907","journal-title":"Eur J Immunol"},{"issue":"5","key":"495_CR78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/jid.2008.356","volume":"129","author":"B Mahe","year":"2009","unstructured":"Mahe B, Vogt A, Liard C, Duffy D, Abadie V, Bonduelle O et al (2009) Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 129(5):1156\u20131164","journal-title":"J Invest Dermatol"},{"issue":"9944","key":"495_CR79","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0140-6736(14)60524-9","volume":"384","author":"L McAllister","year":"2014","unstructured":"McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N et al (2014) Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet 384(9944):674\u2013681","journal-title":"Lancet"},{"issue":"18","key":"495_CR80","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1016\/j.vaccine.2007.01.043","volume":"25","author":"R McKenzie","year":"2007","unstructured":"McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K et al (2007) Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25(18):3684\u20133691","journal-title":"Vaccine"},{"issue":"2","key":"495_CR81","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.immuni.2008.11.013","volume":"30","author":"JB McLachlan","year":"2009","unstructured":"McLachlan JB, Catron DM, Moon JJ, Jenkins MK (2009) Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity 30(2):277\u2013288","journal-title":"Immunity"},{"issue":"9","key":"495_CR82","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1084\/jem.20082874","volume":"206","author":"SM McWhirter","year":"2009","unstructured":"McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT et al (2009) A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 206(9):1899\u20131911","journal-title":"J Exp Med"},{"issue":"6","key":"495_CR83","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.0818-9641.2004.01279.x","volume":"82","author":"C Mesa","year":"2004","unstructured":"Mesa C, Fernandez LE (2004) Challenges facing adjuvants for cancer immunotherapy. Immunol Cell Biol 82(6):644\u2013650","journal-title":"Immunol Cell Biol"},{"issue":"20","key":"495_CR84","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","volume":"27","author":"P Minor","year":"2009","unstructured":"Minor P (2009) Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27(20):2649\u20132652","journal-title":"Vaccine"},{"issue":"12","key":"495_CR85","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nri1728","volume":"5","author":"S Mitragotri","year":"2005","unstructured":"Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5(12):905\u2013916","journal-title":"Nat Rev Immunol"},{"issue":"34","key":"495_CR86","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1016\/j.vaccine.2012.12.048","volume":"31","author":"A Mittal","year":"2013","unstructured":"Mittal A, Raber AS, Schaefer UF, Weissmann S, Ebensen T, Schulze K et al (2013) Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine 31(34):3442\u20133451","journal-title":"Vaccine"},{"key":"495_CR87","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jconrel.2015.03.017","volume":"206","author":"A Mittal","year":"2015","unstructured":"Mittal A, Schulze K, Ebensen T, Weissmann S, Hansen S, Guzman CA et al (2015a) Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination. J Controlled Release (official journal of the Controlled Release Society) 206:140\u2013152","journal-title":"J Controlled Release (official journal of the Controlled Release Society)"},{"issue":"1","key":"495_CR88","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.nano.2014.08.009","volume":"11","author":"A Mittal","year":"2015","unstructured":"Mittal A, Schulze K, Ebensen T, Weissmann S, Hansen S, Lehr CM et al (2015b) Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation. Nanomed Nanotechnol Biol Med 11(1):147\u2013154","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"495_CR89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2045-7022-2-22","volume":"2","author":"L Mondoulet","year":"2012","unstructured":"Mondoulet L, Dioszeghy V, Puteaux E, Ligouis M, Dhelft V, Letourneur F et al (2012) Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy 2(1):22","journal-title":"Clin Transl Allergy"},{"issue":"9","key":"495_CR90","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","author":"M Mutsch","year":"2004","unstructured":"Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T et al (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell\u2019s palsy in Switzerland. N Engl J Med 350(9):896\u2013903","journal-title":"N Engl J Med"},{"issue":"21","key":"495_CR91","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.vaccine.2015.03.096","volume":"33","author":"D Newsted","year":"2015","unstructured":"Newsted D, Fallahi F, Golshani A, Azizi A (2015) Advances and challenges in mucosal adjuvant technology. Vaccine 33(21):2399\u20132405","journal-title":"Vaccine"},{"issue":"1","key":"495_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.2042-7158.1998.tb03298.x","volume":"50","author":"DT O\u2019Hagan","year":"1998","unstructured":"O\u2019Hagan DT (1998) Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 50(1):1\u201310","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"495_CR93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1357-4310(96)10058-7","volume":"3","author":"DT O\u2019Hagan","year":"1997","unstructured":"O\u2019Hagan DT, Ott GS, Van Nest G (1997) Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 3(2):69\u201375","journal-title":"Mol Med Today"},{"issue":"19","key":"495_CR94","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S1359-6446(04)03234-9","volume":"9","author":"DT O\u2019Hagan","year":"2004","unstructured":"O\u2019Hagan DT, Rappuoli R (2004) The safety of vaccines. Drug Discov Today 9(19):846\u2013854","journal-title":"Drug Discov Today"},{"issue":"12","key":"495_CR95","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1586\/erv.09.136","volume":"8","author":"M O\u2019Ryan","year":"2009","unstructured":"O\u2019Ryan M, Linhares AC (2009) Update on Rotarix: an oral human rotavirus vaccine. Expert Rev Vaccines 8(12):1627\u20131641","journal-title":"Expert Rev Vaccines"},{"key":"495_CR96","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","volume":"6","author":"G Ott","year":"1995","unstructured":"Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277\u2013296","journal-title":"Pharm Biotechnol"},{"issue":"5","key":"495_CR97","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1586\/14760584.5.5.617","volume":"5","author":"P Patel","year":"2006","unstructured":"Patel P, Salapatek AM (2006) Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev vaccines 5(5):617\u2013629","journal-title":"Expert Rev vaccines"},{"issue":"2","key":"495_CR98","first-page":"305","volume":"42","author":"S Pattanayak","year":"1970","unstructured":"Pattanayak S, Arora DD, Sehgal CL, Raghavan NG, Topa PK, Subrahmanyam YK (1970) Comparative studies of smallpox vaccination by the bifurcated needle and rotary lancet techniques. Bull World Health Organ 42(2):305\u2013310","journal-title":"Bull World Health Organ"},{"issue":"5","key":"495_CR99","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4161\/hv.19568","volume":"8","author":"Gabriel Pedersen","year":"2012","unstructured":"Pedersen G, Cox R (2012) The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. Hum Vaccines Immunotherapeutics 8(5):689\u2013693","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"10 Suppl","key":"495_CR100","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/S0966-842X(02)02426-5","volume":"10","author":"DH Persing","year":"2002","unstructured":"Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM et al (2002) Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 10(10 Suppl):S32\u2013S37","journal-title":"Trends Microbiol"},{"key":"495_CR101","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.01.107","volume":"24","author":"Nikolai Petrovsky","year":"2006","unstructured":"Petrovsky N (2006) Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 24(Suppl 2):S2-26-29","journal-title":"Vaccine"},{"issue":"5","key":"495_CR102","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82(5):488\u2013496","journal-title":"Immunol Cell Biol"},{"issue":"11","key":"495_CR200","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.vaccine.2012.12.082","volume":"31","author":"Benjaluck Phonrat","year":"2013","unstructured":"Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, et al. (2013) Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine 31(11):1503\u20131509.","journal-title":"Vaccine"},{"issue":"4\u20135","key":"495_CR103","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1438-4221(00)80064-8","volume":"290","author":"M Pizza","year":"2000","unstructured":"Pizza M, Giuliani MM, Fontana MR, Douce G, Dougan G, Rappuoli R (2000) LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. Int J Med Microbiol 290(4\u20135):455\u2013461","journal-title":"Int J Med Microbiol"},{"issue":"17\u201319","key":"495_CR104","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","volume":"19","author":"M Pizza","year":"2001","unstructured":"Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G et al (2001) Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19(17\u201319):2534\u20132541","journal-title":"Vaccine"},{"issue":"2","key":"495_CR105","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1586\/14760584.2.2.197","volume":"2","author":"A Podda","year":"2003","unstructured":"Podda A, Del Giudice G (2003) MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2(2):197\u2013203","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"495_CR106","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cytogfr.2014.07.010","volume":"25","author":"C Ranasinghe","year":"2014","unstructured":"Ranasinghe C, Trivedi S, Wijesundara DK, Jackson RJ (2014) IL-4 and IL-13 receptors: roles in immunity and powerful vaccine adjuvants. Cytokine Growth Factor Rev 25(4):437\u2013442","journal-title":"Cytokine Growth Factor Rev"},{"key":"495_CR107","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2013.12.022","volume":"176","author":"Fiorenza Rancan","year":"2014","unstructured":"Rancan F, Amselgruber S, Hadam S, Munier S, Pavot V, Verrier B et al (2013) Particle-based transcutaneous administration of HIV-1 p24 protein to human skin explants and targeting of epidermal antigen presenting cells. J Control Release 176:115\u2013122","journal-title":"Journal of Controlled Release"},{"issue":"12","key":"495_CR108","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","volume":"11","author":"R Rappuoli","year":"2011","unstructured":"Rappuoli R, Mandl CW, Black S, De Gregorio E (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11(12):865\u2013872","journal-title":"Nat Rev Immunol"},{"issue":"35","key":"495_CR109","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1016\/j.vaccine.2005.04.021","volume":"23","author":"RC Read","year":"2005","unstructured":"Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A et al (2005) Effective nasal influenza vaccine delivery using chitosan. Vaccine 23(35):4367\u20134374","journal-title":"Vaccine"},{"issue":"10","key":"495_CR110","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/1521-4141(2002010)32:10<2857::AID-IMMU2857>3.0.CO;2-R","volume":"32","author":"F Rharbaoui","year":"2002","unstructured":"Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B et al (2002) The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32(10):2857\u20132865","journal-title":"Eur J Immunol"},{"issue":"1","key":"495_CR111","doi-asserted-by":"publisher","first-page":"50","DOI":"10.7774\/cevr.2012.1.1.50","volume":"1","author":"JH Rhee","year":"2012","unstructured":"Rhee JH, Lee SE, Kim SY (2012) Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 1(1):50\u201363","journal-title":"Clin Exp Vaccine Res"},{"issue":"10","key":"495_CR112","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1517\/17425247.2014.931936","volume":"11","author":"P Riese","year":"2014","unstructured":"Riese P, Sakthivel P, Trittel S, Guzm\u00e1n CA (2014) Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv 11(10):1619\u20131634","journal-title":"Expert Opin Drug Deliv"},{"issue":"20","key":"495_CR113","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.2174\/15680266113136660183","volume":"13","author":"P Riese","year":"2013","unstructured":"Riese P, Schulze K, Ebensen T, Prochnow B, Guzman CA (2013) Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem 13(20):2562\u20132580","journal-title":"Curr Top Med Chem"},{"issue":"5","key":"495_CR114","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/erv.12.31","volume":"11","author":"MA Rose","year":"2012","unstructured":"Rose MA, Zielen S, Baumann U (2012) Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 11(5):595\u2013607","journal-title":"Expert Rev Vaccines"},{"key":"495_CR115","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1479-5876-10-144","volume":"10","author":"N Ruffin","year":"2012","unstructured":"Ruffin N, Borggren M, Euler Z, Fiorino F, Grupping K, Hallengard D et al (2012) Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. J Transl Med 10:144","journal-title":"J Transl Med"},{"issue":"1","key":"495_CR116","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa052434","volume":"354","author":"GM Ruiz-Palacios","year":"2006","unstructured":"Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC et al (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354(1):11\u201322","journal-title":"N Engl J Med"},{"key":"495_CR117","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1155\/2015\/794601","volume":"2015","author":"E Sah","year":"2015","unstructured":"Sah E, Sah H (2015) Recent trends in preparation of poly(lactide-co-glycolide) nanoparticles by mixing polymeric organic solution with antisolvent. J Nanomaterials 2015:22","journal-title":"J Nanomaterials"},{"issue":"8","key":"495_CR118","doi-asserted-by":"publisher","first-page":"e104824","DOI":"10.1371\/journal.pone.0104824","volume":"9","author":"MV Sanchez","year":"2014","unstructured":"Sanchez MV, Ebensen T, Schulze K, Cargnelutti D, Blazejewska P, Scodeller EA et al (2014) Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One 9(8):e104824","journal-title":"PLoS One"},{"issue":"6","key":"495_CR119","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1172\/JCI34584","volume":"118","author":"D Sancho","year":"2008","unstructured":"Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ et al (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Investig 118(6):2098\u20132110","journal-title":"J Clin Investig"},{"issue":"1","key":"495_CR120","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/vaccines3010148","volume":"3","author":"HF Savelkoul","year":"2015","unstructured":"Savelkoul HF, Ferro VA, Strioga MM, Schijns VE (2015) Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines (Basel) 3(1):148\u2013171","journal-title":"Vaccines (Basel)"},{"issue":"11","key":"495_CR121","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/iub.1212","volume":"65","author":"P Schaap","year":"2013","unstructured":"Schaap P (2013) Cyclic di-nucleotide signaling enters the eukaryote domain. IUBMB Life 65(11):897\u2013903","journal-title":"IUBMB Life"},{"issue":"3","key":"495_CR122","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1586\/14760584.6.3.391","volume":"6","author":"CS Schmidt","year":"2007","unstructured":"Schmidt CS, Morrow WJ, Sheikh NA (2007) Smart adjuvants. Expert Rev Vaccines 6(3):391\u2013400","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"495_CR123","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder RA, Darrah PA, Roederer M (2008a) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8(4):247\u2013258","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"495_CR124","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"Robert A. Seder","year":"2008","unstructured":"Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8(6):247","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"495_CR125","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.biotechadv.2014.12.004","volume":"33","author":"R Sharma","year":"2015","unstructured":"Sharma R, Agrawal U, Mody N, Vyas SP (2015) Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities. Biotechnol Adv 33(1):64\u201379","journal-title":"Biotechnol Adv"},{"issue":"1","key":"495_CR126","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.0105-2896.2009.00870.x","volume":"234","author":"K Shortman","year":"2010","unstructured":"Shortman K, Heath WR (2010) The CD8+\u00a0dendritic cell subset. Immunol Rev 234(1):18\u201331","journal-title":"Immunol Rev"},{"issue":"7","key":"495_CR127","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nsmb.2331","volume":"19","author":"C Shu","year":"2012","unstructured":"Shu C, Yi G, Watts T, Kao CC, Li P (2012) Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol 19(7):722\u2013724","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"495_CR128","doi-asserted-by":"publisher","first-page":"e95728","DOI":"10.1371\/journal.pone.0095728","volume":"9","author":"I Skrnjug","year":"2014","unstructured":"Skrnjug I, Rueckert C, Libanova R, Lienenklaus S, Weiss S, Guzman CA (2014) The mucosal adjuvant cyclic di-AMP exerts immune stimulatory effects on dendritic cells and macrophages. PLoS One 9(4):e95728","journal-title":"PLoS One"},{"issue":"4","key":"495_CR129","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/apm.12351","volume":"123","author":"A Srivastava","year":"2015","unstructured":"Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M (2015) Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS 123(4):275\u2013288","journal-title":"APMIS"},{"issue":"7","key":"495_CR130","doi-asserted-by":"publisher","first-page":"e102664","DOI":"10.1371\/journal.pone.0102664","volume":"9","author":"P Stein","year":"2014","unstructured":"Stein P, Gogoll K, Tenzer S, Schild H, Stevanovic S, Langguth P et al (2014) Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation. PLoS One 9(7):e102664","journal-title":"PLoS One"},{"issue":"3","key":"495_CR131","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1377\/hlthaff.24.3.611","volume":"24","author":"AM Stern","year":"2005","unstructured":"Stern AM, Markel H (2005) The history of vaccines and immunization: familiar patterns, new challenges. Health Aff 24(3):611\u2013621","journal-title":"Health Aff"},{"issue":"1","key":"495_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570162043485004","volume":"2","author":"L Stevceva","year":"2004","unstructured":"Stevceva L, Strober W (2004) Mucosal HIV vaccines: where are we now? Curr HIV Res 2(1):1\u201310","journal-title":"Curr HIV Res"},{"issue":"9753","key":"495_CR133","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/S0140-6736(10)61230-5","volume":"376","author":"RW Sutter","year":"2010","unstructured":"Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H et al (2010) Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 376(9753):1682\u20131688","journal-title":"Lancet"},{"issue":"2","key":"495_CR134","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2012.11.015","volume":"166","author":"LJ Thomann-Harwood","year":"2013","unstructured":"Thomann-Harwood LJ, Kaeuper P, Rossi N, Milona P, Herrmann B, McCullough KC (2013) Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation. J Control Release 166(2):95\u2013105","journal-title":"J Control Release"},{"issue":"2","key":"495_CR135","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.4049\/jimmunol.1000808","volume":"186","author":"T Tsuji","year":"2011","unstructured":"Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ et al (2011) Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8\u00a0+\u00a0and CD4\u00a0+\u00a0T cell responses with broad antigen specificity. J Immunol 186(2):1218\u20131227","journal-title":"J Immunol"},{"issue":"6","key":"495_CR136","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1440-1711.2004.01288.x","volume":"82","author":"M Vajdy","year":"2004","unstructured":"Vajdy M, Srivastava I, Polo J, Donnelly J, O\u2019Hagan D, Singh M (2004) Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 82(6):617\u2013627","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"495_CR137","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0966-842X(00)88907-6","volume":"3","author":"GP van den Dobbelsteen","year":"1995","unstructured":"van den Dobbelsteen GP, van Rees EP (1995) Mucosal immune responses to pneumococcal polysaccharides: implications for vaccination. Trends Microbiol 3(4):155\u2013159","journal-title":"Trends Microbiol"},{"issue":"2","key":"495_CR138","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.molimm.2012.10.031","volume":"55","author":"Y van Kooyk","year":"2013","unstructured":"van Kooyk Y, Unger WW, Fehres CM, Kalay H, Garcia-Vallejo JJ (2013) Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol 55(2):143\u2013145","journal-title":"Mol Immunol"},{"issue":"22","key":"495_CR139","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1016\/j.vaccine.2006.03.025","volume":"24","author":"T Vesikari","year":"2006","unstructured":"Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG et al (2006) Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24(22):4821\u20134829","journal-title":"Vaccine"},{"issue":"2","key":"495_CR140","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.vaccine.2009.10.041","volume":"28","author":"T Vesikari","year":"2009","unstructured":"Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U et al (2009) RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 28(2):345\u2013351","journal-title":"Vaccine"},{"key":"495_CR141","first-page":"121","volume":"354","author":"SH Wang","year":"2012","unstructured":"Wang SH, Thompson AL, Hickey AJ, Staats HF (2012) Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery. Curr Top Microbiol Immunol 354:121\u2013156","journal-title":"Curr Top Microbiol Immunol"},{"issue":"36","key":"495_CR142","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.2174\/1381612821666150923100147","volume":"21","author":"Ting Wang","year":"2015","unstructured":"Wang T, Wang N (2015) Biocompatible mater constructed microneedle arrays as a novel vaccine adjuvant-delivery system for cutaneous and mucosal vaccination. Curr Pharm Des 21:5245\u20135255","journal-title":"Current Pharmaceutical Design"},{"issue":"3","key":"495_CR143","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s13238-014-0125-1","volume":"6","author":"X Wang","year":"2015","unstructured":"Wang X, Meng D (2015) Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell 6(3):170\u2013184","journal-title":"Protein Cell"},{"issue":"2","key":"495_CR144","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/exd.12083","volume":"22","author":"I Wanke","year":"2013","unstructured":"Wanke I, Skabytska Y, Kraft B, Peschel A, Biedermann T, Schittek B (2013) Staphylococcus aureus skin colonization is promoted by barrier disruption and leads to local inflammation. Exp Dermatol 22(2):153\u2013155","journal-title":"Exp Dermatol"},{"key":"495_CR145","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-bioeng-071811-150054","volume":"14","author":"KA Woodrow","year":"2012","unstructured":"Woodrow KA, Bennett KM, Lo DD (2012) Mucosal vaccine design and delivery. Annu Rev Biomed Eng 14:17\u201346","journal-title":"Annu Rev Biomed Eng"},{"issue":"44","key":"495_CR146","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1016\/j.vaccine.2015.07.101","volume":"33","author":"Yufei Xia","year":"2015","unstructured":"Xia Y, Fan Q, Hao D, Wu J, Ma G, Su Z (2015) Chitosan-based mucosal adjuvants: sunrise on the ocean. Vaccine 44:5997\u20136010","journal-title":"Vaccine"},{"issue":"8","key":"495_CR147","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1517\/14712598.2010.496776","volume":"10","author":"M Yu","year":"2010","unstructured":"Yu M, Vajdy M (2010) Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 10(8):1181\u20131195","journal-title":"Expert Opin Biol Ther"}],"container-title":["Current Topics in Microbiology and Immunology","How to Overcome the Antibiotic Crisis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2016_495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T19:50:44Z","timestamp":1675885844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2016_495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319492827","9783319492841"],"references-count":148,"URL":"https:\/\/doi.org\/10.1007\/82_2016_495","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"type":"print","value":"0070-217X"},{"type":"electronic","value":"2196-9965"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"2 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}